Claritas Rx’s Post

💊 Walgreens is stepping up its game with a big move into gene and cell therapy services. Yep, you heard it right! 📢 The neighborhood pharmacy giant is now offering these cutting-edge therapies, housed in a dedicated 18,000-square-foot center in Pittsburgh. This expansion comes as part of Walgreens' broader strategy to tap into fast-growing areas of healthcare, and it's a smart move. With gene therapies gaining FDA approval for conditions like sickle cell disease, it's clear that the future of medicine is here. 💊 What's really cool is how Walgreens is integrating these services into its existing specialty pharmacy business. By bringing together its assets under the new Walgreens Specialty Pharmacy unit, the company is streamlining its offerings and making it easier for patients to access specialized treatments. 📢 And it's not just about the medications. Walgreens is also focused on providing comprehensive care, with services like injection training, medication side-effect management, and financial assistance coordination. It's a one-stop-shop for patients facing complex health challenges. #HealthcareInnovation #GeneTherapy #CellTherapy #HealthTech

NEW 📰 in International Clinical Trials: Cutting-edge cell and gene therapies come with increasing complexities around cold-chain logistics. How can clinical supply chains meet these evolving challenges? Read the article by Clinigen’s VP of EU Operations Gunter Van Hoof to learn how trial sites, HCPs and patients can receive the necessary medications precisely when needed through an unbroken supply chain.   https://lnkd.in/gqTcSp-D   #clinicaltrials #coldchainmanagement #cellandgene #clinicalsupplies #coldchain

Thoughts on this? >> bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy - Business Wire >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #healthcare #biotech #competitivemarketing

𝐀𝐑𝐏𝐄𝐘𝐎® 𝐑𝐞𝐜𝐞𝐢𝐯𝐞𝐬 𝐅𝐮𝐥𝐥 𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥, 𝐚 𝐌𝐚𝐣𝐨𝐫 𝐋𝐞𝐚𝐩 𝐅𝐨𝐫𝐰𝐚𝐫𝐝 𝐢𝐧 𝐈𝐠𝐀 𝐍𝐞𝐩𝐡𝐫𝐨𝐩𝐚𝐭𝐡𝐲 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 Calliditas Therapeutics Calliditas Therapeutics is thrilled to announce the full FDA approval of TARPEYO® for the treatment of IgA nephropathy (IgAN). TARPEYO, an FDA-approved gene therapy, is the first-ever treatment for IgAN to receive full approval based on a measure of kidney function. This marks a significant advancement in the battle against IgAN. Key Points: TARPEYO is the only FDA-approved treatment for IgAN, demonstrating a substantial reduction in the loss of kidney function. The approval is based on robust data from the Phase 3 NefIgArd clinical trial, showcasing TARPEYO's efficacy and safety in adults with primary IgAN at risk for disease progression. Over a 2-year period, TARPEYO showed a 50% reduction in the deterioration of kidney function compared to the placebo group. TARPEYO's impact on proteinuria reduction, combined with its durability, underscores its potential as a disease-modifying agent in IgAN. The FDA approval is for adults with primary IgAN at risk of disease progression, regardless of proteinuria levels. Richard Lafayette Richard Lafayette, MD, FACP, from Stanford Healthcare, emphasizes TARPEYO's potential as a disease-modifying agent. This approval opens doors for adult IgAN patients at risk, providing them with an effective treatment option to improve disease outcomes. CEO Renee Aguiar-Lucander Renee Aguiar-Lucander expresses gratitude to the team, investigators, patients, and caregivers who made this milestone possible. TARPEYO is now available exclusively through Calliditas specialty pharmacy, Biologics by McKesson. #MedicalBreakthrough #IgAN #FDAApproval #pharmaceutical #Biological #patient #treatment #nephropathy #clinicaltrials

🧠 A new #Alzheimers pill, ALZ-801, is on the horizon! 💊 Unlike current infusion treatments, this pill targets amyloid proteins differently and may be safer for those with the Alzheimer's gene, #ApoE4. Learn more about this potential breakthrough in Alzheimer's treatment from Being Patient's Simon Spichak 👇

Daily notebook from the J.P. Morgan Healthcare Conference: Big pharma execs weigh in on business development strategy, Sage CEO Barry Green discusses how the Inflation Reduction Act should spur deal-making and bluebird talks about gene therapy commercialization plans.  #pharma #genetherapy #businessdevelopment #ceo #strategy #healthcare

As cell and gene therapies continue to gain traction and win approvals, record-breaking list prices highlight the need for objective drug pricing valuations in the US. #ICER has taken on the role of the nation’s drug pricing watchdog, but questions surrounding the organization’s influence and effectiveness remain. In our latest blog, we assess the impact ICER’s value-based assessments have on pricing and access for cell and gene therapies in the U.S.  https://bit.ly/3o5mo0a #CellAndGeneTherapy #DrugPricing  Tom Fitzsimons, Ned Wydysh, Vivek Mittal

Thoughts on this? >> Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort ... - GlobeNewswire >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #healthcare #biotech #competitivemarketing

Thoughts on this? >> bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy - Yahoo Finance >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #competitivemarketing #biotech #healthcare

Thoughts on this? >> Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort ... - GlobeNewswire >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #healthcare #pharmaceutical #pharma